Day: January 5, 2022

Oslo, Norway and Seoul, South Korea 5 January, 2022 – PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharmaceutical company and MDimune Inc. (“MDimune”), a private South Korean biotech company developing innovative drug delivery technologies for modifying cellular and disease processes in many areas of human disease, today announced a preclinical research collaboration that would offer several opportunities for future development. Commenting on the announcement, Per Walday, CEO of PCI Biotech, said: “We are very pleased to initiate a collaboration with MDimune. This collaboration is an additional mark of interest from a cutting-edge biotech company developing therapies with emerging advanced technologies, with a large potential in future medicine.“ Seung Wook Oh, Chief Scientific Officer of MDimune added: “We are excited...

Calgary, AB – Canada | January 03, 2022 — Credit has become the necessity of time. People rely on credit to support themselves in financial matters and enjoy the various other benefits offered by it to the users. But most of them fail to get the maximum benefit out of it, as they have bad credit history. The Credit Resources program is something that gives you effective results and helps you enjoy all the benefits offered by credit companies and banks. Credit Resources have turned out to be the leading company that helps users enjoy the benefits of amazing credit. The company launched its recent program that will guide the users through strategic ways to improve their credit scores. The company has introduced its users with the 4 effective ways that can help them improve the score of their credit reports. ● The company helps...

Clover expects to recruit hundreds of new hires in the area to support preclinical development, process development and pilot manufacturing for novel vaccines and treatments based on Trimer-Tag™ platform and beyond CHENGDU, China, Jan. 05, 2022 (GLOBE NEWSWIRE) — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced today it has started construction on a new R&D Center in Zhangjiang Biotech and Pharmaceutical Industrial Base, dubbed “Zhangjiang Pharma Valley”, located in Zhangjiang Hi-Tech Park in Pudong, Shanghai. The Zhangjiang Pharma Valley is one of the top biotech hubs in China and is home to over 1,000 innovative biotechnology and biopharmaceutical companies. Clover has access to over 25,000...

VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) — Metallica Metals Corp. (CSE: MM) (OTC: MTALF) (FWB: SY7P) (the “Company” or “Metallica Metals”) announces a correction to the finder fees paid in a non-brokered private placement (the “Private Placement”) announced in a news release issued December 22, 2021. The Company paid finder’s fee of $6,398.00 in cash, issued a total of 419,440 Units on the same terms as the NFT Units and issued 400,303 finder’s warrants (“Finder’s Warrants”). Each Finder’s Warrant is exercisable to acquire one additional common share at a price of $0.25 per Warrant for a period of two years from issuance. In all other respects, the news release of December 22, 2021 remains the same. On behalf of the Board of Directors METALLICA METALS CORP.Paul Ténière, M.Sc., P.Geo.President and Directorinfo@metallica-metals.comHead...

Great Place to Work BadgeIndia CertificationHYDERABAD, INDIA, Jan. 05, 2022 (GLOBE NEWSWIRE) — Leading global data analytics provider Verisk (NASDAQ: VRSK) has been Great Place to Work-Certified™ in India for the second year in a row. Based on employee feedback, the certification honors Verisk for its outstanding workplace culture. Verisk’s certification is driven by an employee engagement survey which measured the extent to which employees across the organization reported a consistently great workplace experience, considering factors such as their daily encounters of innovation, inclusivity, company values and the effectiveness of its leaders. Verisk has created a Great Place to Work FOR ALL their employees by excelling on the five dimensions of a High-Trust, High-Performance Culture™ – Credibility, Respect, Fairness,...

Sixth-Generation Device Automatically Adapts to All Environments for an Enhanced Hearing Experience LAS VEGAS, Jan. 04, 2022 (GLOBE NEWSWIRE) — Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today launched Eargo 6, its sixth-generation FDA Class II exempt hearing aid and most powerful device yet, at CES 2022. Eargo 6’s new Sound Adjust technology is an example of better hearing, made effortless. Its proprietary algorithm identifies the user’s surroundings and instantly modifies the hearing device’s settings to ensure optimal benefit, without requiring manual input from the wearer. Eargo 6 also introduces a new environmental offset called “mask mode” to offset the communication challenges faced by individuals with hearing loss while conversing with someone...